Effect of the cumulative dose of zoledronic acid on the pathogenesis of osteonecrosis of the jaws

Günaldi,Meral; Afsar,Cigdem  Usul; Duman,Berna  Bozkurt; Kara,Ismail  Oguz; Tatli,Ufuk; Sahi̇n,Berksoy

doi:10.3892/ol.2015.3156

Effect of the cumulative dose of zoledronic acid on the pathogenesis of osteonecrosis of the jaws

Authors:
- Meral Günaldi
- Cigdem Usul Afsar
- Berna Bozkurt Duman
- Ismail Oguz Kara
- Ufuk Tatli
- Berksoy Sahi̇n
View Affiliations

Affiliations: Department of Medical Oncology, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey, Department of Medical Oncology, Cukurova University Medical School, Adana, Adana, Turkey, Department of Medical Oncology, Adana Research and Training Hospital, Adana, Adana, Turkey, Faculty of Dentistry, Cukurova University, Adana, Adana, Turkey
Published online on: April 27, 2015 https://doi.org/10.3892/ol.2015.3156
Pages: 439-442

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is a severe bone disease for which the pathogenetic mechanisms and risk factors are not fully understood. The present study evaluated the data of 652 patients with bone metastasis that had undergone treatment with biphosphonates. Subsequently, 24 patients with BRONJ and 20 control patients without BRONJ that were treated with zoledronic acid were enrolled. It was found that BRONJ occurred in 3.6% of patients. The mean age and the administration of dental treatment were found to be significantly associated with BRONJ development (P=0.049 and P=0.013, respectively). The cumulative dose median in the BRONJ group was found to be significantly higher compared with the cumulative dose average in the control group (P=0.037). In addition, at the time of BRONJ development, improvement in the disease was determined to be better in the BRONJ group than in the control group (P=0.031). The present study determined that age, the existence of dental extraction and the cumulative dose of zoledronate were all important risk factors in BRONJ development.

View Figures

View References

1	Black DM, Cummings SR, Karpf DB, et al: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Fracture Intervention Trial Research Group. Lancet. 348:1535–1541. 1996. View Article : Google Scholar : PubMed/NCBI
2	Berenson JR, Hillner BE, Kyle RA, et al: American Society of Clinical Oncology Bisphosphonates Expert Panel: American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol. 20:3719–3736. 2002. View Article : Google Scholar : PubMed/NCBI
3	Fleisch H: Bisphosphonates: Mechanisms of action. Endocr Rev. 19:80–100. 1998. View Article : Google Scholar : PubMed/NCBI
4	Russell RG, Croucher PI and Rogers MJ: Bisphosphonates: Pharmacology, mechanisms of action and clinical uses. Osteoporos Int. 9(Suppl 2): S66–S80. 1999.PubMed/NCBI
5	Löwik CW, van der Pluijm G, van der Wee-Pals LJ, et al: Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. J Bone Miner Res. 3:185–192. 1988.PubMed/NCBI
6	Piper K, Boyde A and Jones SJ: The effect of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (ADP) on the resorptive function of osteoclasts of known nuclear number. Calcif Tissue Int. 54:56–61. 1994. View Article : Google Scholar : PubMed/NCBI
7	Hughes DE, Wright KR, Uy HL, et al: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 10:1478–1487. 1995.PubMed/NCBI
8	Reszka AA, Halasy-Nagy JM, Masarachia PJ, et al: Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem. 274:34967–34973. 1999. View Article : Google Scholar : PubMed/NCBI
9	Diel IJ, Solomayer EF and Bastert G: Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies. Cancer. 88:3080–3088. 2000. View Article : Google Scholar : PubMed/NCBI
10	Pietschmann P, Stohlawetz P, Brosch S, et al: The effect of alendronate on cytokine production, adhesion molecule expression and transendothelial migration of human peripheral blood mononuclear cells. Calcif Tissue Int. 63:325–330. 1998. View Article : Google Scholar : PubMed/NCBI
11	Ledoux D, Hamma-Kourbali Y, Di Benedetto M, et al: A new dimethyl ester bisphosphonate inhibits angiogenesis and growth of human epidermoid carcinoma xenograft in nude mice. Anticancer Drugs. 17:479–485. 2006. View Article : Google Scholar : PubMed/NCBI
12	Rogers MJ, Watts DJ and Russell RG: Overview of bisphosphonates. Cancer. 80(Suppl): 1652–1660. 1997.PubMed/NCBI
13	Boonyapakorn T, Schirmer I, Reichart PA, et al: Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 44:857–869. 2008. View Article : Google Scholar : PubMed/NCBI
14	Green J and Clézardin P: The molecular basis of bisphosphonate activity: a preclinical perspective. Semin Oncol. 37(Suppl 1): S3–S11. 2010.PubMed/NCBI
15	Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg. 61:1115–1117. 2003. View Article : Google Scholar : PubMed/NCBI
16	Janovská Z: Bisphosphonate-related osteonecrosis of the jaws A severe side effect of bisphosphonate therapy. Acta Medica (Hradec Kralove). 55:111–115. 2012.PubMed/NCBI
17	Ferlito S, Puzzo S, Palermo F and Verzì P: Treatment of bisphosphonate-related osteonecrosis of the jaws: presentation of a protocol and an observational longitudinal study of an Italian series of cases. Br J Oral Maxillofac Surg. 50:425–429. 2012. View Article : Google Scholar : PubMed/NCBI
18	McLeod NM, Brennan PA and Ruggiero SL: Bisphosphonate osteonecrosis of the jaw: A historical and contemporary review. Surgeon. 10:36–42. 2012. View Article : Google Scholar : PubMed/NCBI
19	Tubiana-Hulin M, Spielmann M, Roux C, et al: Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis. Crit Rev Oncol Hematol. 71:12–21. 2009. View Article : Google Scholar : PubMed/NCBI
20	Ruggiero SL, Dodson TB, Assael LA, et al: Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw − 2009 update. Aust Endod J. 35:119–130. 2009.PubMed/NCBI
21	Hoff AO, Toth BB, Altundag K, et al: Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 23:826–836. 2008. View Article : Google Scholar : PubMed/NCBI
22	Bamias A, Kastritis E, Bamia C, et al: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol. 23:8580–8587. 2005. View Article : Google Scholar : PubMed/NCBI
23	Thumbigere-Math V, Tu L, Huckabay S, et al: A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. Am J Clin Oncol. 35:386–392. 2012. View Article : Google Scholar : PubMed/NCBI
24	Brufsky AM, Sereika SM, Mathew A, et al: Long-term treatment with intravenous bisphosphonates in metastatic breast cancer: A retrospective study. Breast J. 19:504–511. 2013.PubMed/NCBI
25	Vahtsevanos K, Kyrgidis A, Verrou E, et al: Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 27:5356–5362. 2009. View Article : Google Scholar : PubMed/NCBI
26	Kos M, Kuebler JF, Luczak K and Engelke W: Bisphosphonate-related osteonecrosis of the jaws: A review of 34 cases and evaluation of risk. J Craniomaxillofac Surg. 38:255–259. 2010. View Article : Google Scholar : PubMed/NCBI
27	Vescovi P, Campisi G, Fusco V, et al: Surgery-triggered and non-surgery-triggered bisphosphonate-related osteonecrosis of the jaws (BRONJ): A retrospective analysis of 567 cases in an Italian multicentre study. Oral Oncol. 47:191–194. 2011. View Article : Google Scholar : PubMed/NCBI
28	Molcho S, Peer A, Berg T, et al: Diabetes microvascular disease and the risk for bisphosphonate-related osteonecrosis of the jaw: a single centre study. J Clin Endocrinol Metab. 98:E1807–E1812. 2013. View Article : Google Scholar : PubMed/NCBI
29	Wessel JH, Dodson TB and Zavras AI: Zoledronate, smoking and obesity are strong risk factors for osteonecrosis of the jaw: A case-control study. J Oral Maxillofac Surg. 66:625–631. 2008. View Article : Google Scholar : PubMed/NCBI
30	Smidt-Hansen T, Folkmar TB, Fode K, et al: Combination of zoledronic acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. J Oral Maxillofac Surg. 71:1532–1540. 2013. View Article : Google Scholar : PubMed/NCBI
31	Lescaille G, Coudert AE, Baaroun V, et al: Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients. Bone. 58:103–107. 2014. View Article : Google Scholar : PubMed/NCBI
32	Fusco V, Porta C, Saia G, et al: Osteonecrosis of the jaw in patients with metastatic renal cell cancer treated with bisphosphonates and targeted agents: Results of an Italian multicenter study and review of the literature. Clin Genitourin Cancer. Dec 9–2014.(Epub ahead of print).
33	McKay RR, Lin X, Perkins JJ, et al: Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. Eur Urol. 66:502–509. 2014. View Article : Google Scholar : PubMed/NCBI
34	McArthur HL, Estilo C, Huryn J, Williams T, Fornier M, Traina TA, Howard J, Hudis CA and Dickler MN: Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC). J Clin Oncol. 26:95882008.